<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>EULAR Sjögren's syndrome disease activity index (ESSDAI)&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">EULAR Sjögren's syndrome disease activity index (ESSDAI)<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">EULAR Sjögren's syndrome disease activity index (ESSDAI)<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup width="20%"></colgroup><colgroup width="10%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Domain</td> <td class="subtitle1">Exclusion(s) and notes</td> <td class="subtitle1">Activity level</td> <td class="subtitle1">Description</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Constitutional</td> <td class="divider_bottom" rowspan="3">Exclusion of fever of infectious origin and voluntary weight loss</td> <td>No = 0</td> <td>Absence of the following symptoms</td> </tr> <tr> <td>Low = 3</td> <td>Mild or intermittent fever (37.5 to 38.5°C)/night sweats and/or involuntary weight loss of 5 to 10% of body weight</td> </tr> <tr class="divider_bottom"> <td>Moderate = 6</td> <td>Fever (&gt;38.5°C)/night sweats and/or involuntary weight loss of &gt;10% of body weight</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Lymphadenopathy and lymphoma</td> <td class="divider_bottom" rowspan="4">Exclusion of infection</td> <td>No = 0</td> <td>Absence of the following features</td> </tr> <tr> <td>Low = 4</td> <td>Lymphadenopathy ≥1 cm in any nodal region or ≥2 cm in inguinal region</td> </tr> <tr> <td>Moderate = 8</td> <td>Lymphadenopathy ≥2 cm in any nodal region or ≥3 cm in inguinal region, and/or splenomegaly (clinically palpable or assessed by imaging)</td> </tr> <tr class="divider_bottom"> <td>High = 12</td> <td>Current malignant B-cell proliferative disorder</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Glandular</td> <td class="divider_bottom" rowspan="3">Exclusion of stone or infection</td> <td>No = 0</td> <td>Absence of glandular swelling</td> </tr> <tr> <td>Low = 2</td> <td>Small glandular swelling with enlarged parotid (≤3 cm), or limited submandibular (≤2 cm) or lacrimal swelling (≤1 cm)</td> </tr> <tr class="divider_bottom"> <td>Moderate = 4</td> <td>Major glandular swelling with enlarged parotid (&gt;3 cm), or important submandibular (&gt;2 cm) or lacrimal swelling (&gt;1 cm)</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Articular</td> <td class="divider_bottom" rowspan="4">Exclusion of osteoarthritis</td> <td>No = 0</td> <td>Absence of currently active articular involvement</td> </tr> <tr> <td>Low = 2</td> <td>Arthralgias in hands, wrists, ankles, and feet accompanied by morning stiffness (&gt;30 minutes)</td> </tr> <tr> <td>Moderate = 4</td> <td>1 to 5 (of 28 total count) synovitis</td> </tr> <tr class="divider_bottom"> <td>High = 6</td> <td>≥6 (of 28 total count) synovitis</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Cutaneous</td> <td class="divider_bottom" rowspan="4">Rate as "no activity" stable long-lasting features related to damage</td> <td>No = 0</td> <td>Absence of currently active cutaneous involvement</td> </tr> <tr> <td>Low = 3</td> <td>Erythema multiforme</td> </tr> <tr> <td>Moderate = 6</td> <td>Limited cutaneous vasculitis, including urticarial vasculitis, or purpura limited to feet and ankles, or subacute cutaneous lupus</td> </tr> <tr class="divider_bottom"> <td>High = 9</td> <td>Diffuse cutaneous vasculitis, including urticarial vasculitis, or diffuse purpura, or ulcers related to vasculitis</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Pulmonary</td> <td class="divider_bottom" rowspan="4">Rate as "no activity" stable long-lasting features related to damage or respiratory involvement not related to the disease (tobacco use, etc)</td> <td>No = 0</td> <td>Absence of currently active pulmonary involvement</td> </tr> <tr> <td>Low = 5</td> <td> <p>Persistent cough <strong>due to</strong> bronchial involvement with no radiographic abnormalities on radiography</p> <p><strong>or</strong></p> Radiologic or HRCT evidence of interstitial lung disease with no breathlessness and normal lung function test </td> </tr> <tr> <td>Moderate = 10</td> <td>Moderately active pulmonary involvement, such as interstitial lung disease shown by HRCT with shortness of breath on exercise (NYHA II) or abnormal lung function tests restricted to DL<sub>CO</sub> &lt;70% and ≥40% or FVC &lt;80% and ≥60%</td> </tr> <tr class="divider_bottom"> <td>High = 15</td> <td>Highly active pulmonary involvement, such as interstitial lung disease shown by HRCT with shortness of breath at rest (NYHA III, IV) or with abnormal lung function tests: DL<sub>CO</sub> &lt;40% or FVC &lt;60%</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Renal</td> <td class="divider_bottom" rowspan="4">Rate as "no activity" stable long-lasting features related to damage and renal involvement not related to the disease. If biopsy has been performed, please rate activity based on histologic features first.</td> <td>No = 0</td> <td>Absence of currently active renal involvement with proteinuria &lt;0.5 g/day, no hematuria, no leukocyturia, no acidosis, or long-lasting stable proteinuria due to damage</td> </tr> <tr> <td>Low = 5</td> <td>Evidence of mild active renal involvement, limited to tubular acidosis without renal failure or glomerular involvement with proteinuria (between 0.5 and 1 g/day) and without hematuria or renal failure (GFR ≥60 mL/minute)</td> </tr> <tr> <td>Moderate = 10</td> <td>Moderately active renal involvement, such as tubular acidosis with renal failure (GFR &lt;60 mL/minute) or glomerular involvement with proteinuria between 1 and 1.5 g/day and without hematuria or renal failure (GFR ≥60 mL/minute) or histologic evidence of extramembranous glomerulonephritis or important interstitial lymphoid infiltrate</td> </tr> <tr class="divider_bottom"> <td>High = 15</td> <td>Highly active renal involvement, such as glomerular involvement with proteinuria &gt;1.5 g/day or hematuria or renal failure (GFR &lt;60 mL/minute), or histologic evidence of proliferative glomerulonephritis or cryoglobulinemia-related renal involvement</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Muscular</td> <td class="divider_bottom" rowspan="4">Exclusion of weakness due to glucocorticoids</td> <td>No = 0</td> <td>Absence of currently active muscular involvement</td> </tr> <tr> <td>Low = 6</td> <td>Mild active myositis shown by abnormal EMG, MRI, or biopsy with no weakness and creatine kinase (CK ≥ULN and ≤2x ULN)</td> </tr> <tr> <td>Moderate = 12</td> <td>Moderately active myositis confirmed by abnormal EMG, MRI, or biopsy with weakness (maximal deficit of 4/5) or elevated creatine kinase (CK &gt;2x ULN and ≤4x ULN)</td> </tr> <tr class="divider_bottom"> <td>High = 18</td> <td>Highly active myositis shown by abnormal EMG, MRI, or biopsy with weakness (deficit ≤3/5) or elevated creatine kinase (&gt;4x ULN)</td> </tr> <tr> <td class="divider_bottom" rowspan="4">PNS</td> <td class="divider_bottom" rowspan="4">Rate as "no activity" stable long-lasting features related to damage or PNS involvement not related to the disease</td> <td>No = 0</td> <td>Absence of currently active PNS involvement</td> </tr> <tr> <td>Low = 5</td> <td> <p>Mild active PNS involvement, such as pure sensory axonal polyneuropathy shown by NCS or trigeminal (V) neuralgia</p> Proven small fiber neuropathy </td> </tr> <tr> <td>Moderate = 10</td> <td> <p>Moderately active PNS involvement shown by NCS, such as axonal sensorimotor neuropathy with maximal motor deficit of 4/5, pure sensory neuropathy with presence of cryoglobulinemic vasculitis, ganglionopathy with symptoms restricted to mild/moderate ataxia, inflammatory demyelinating polyneuropathy (CIDP) with mild functional impairment (maximal motor deficit of 4/5 or mild ataxia)</p> <p><strong>or</strong></p> Cranial nerve involvement of peripheral origin (except trigeminal [V] neuralgia) </td> </tr> <tr class="divider_bottom"> <td>High = 15</td> <td>Highly active PNS involvement shown by NCS, such as axonal sensorimotor neuropathy with motor deficit ≤3/5, peripheral nerve involvement due to vasculitis (mononeuritis multiplex, etc), severe ataxia due to ganglionopathy, inflammatory demyelinating polyneuropathy (CIDP) with severe functional impairment (motor deficit ≤3/5 or severe ataxia)</td> </tr> <tr> <td class="divider_bottom" rowspan="3">CNS</td> <td class="divider_bottom" rowspan="3">Rate as "no activity" stable long-lasting features related to damage or CNS involvement not related to the disease</td> <td>No = 0</td> <td>Absence of currently active CNS involvement</td> </tr> <tr> <td>Moderate = 10</td> <td>Moderately active CNS features, such as cranial nerve involvement of central origin, optic neuritis or multiple sclerosis-like syndrome with symptoms restricted to pure sensory impairment or confirmed cognitive impairment</td> </tr> <tr class="divider_bottom"> <td>High = 15</td> <td>Highly active CNS features, such as cerebral vasculitis with cerebrovascular accident or transient ischemic attack, seizures, transverse myelitis, lymphocytic meningitis, multiple sclerosis-like symptoms with motor deficit</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Hematologic</td> <td class="divider_bottom" rowspan="4"> <p>For anemia, neutropenia, and thrombocytopenia, only autoimmune cytopenia must be considered</p> Exclusion of vitamin or iron deficiency, drug-induced cytopenia </td> <td>No = 0</td> <td>Absence of autoimmune cytopenia</td> </tr> <tr> <td>Low = 2</td> <td> <p>Cytopenia of autoimmune origin with neutropenia (ANC &gt;1000 and &lt;1500/mm<sup>3</sup>) and/or anemia (hemoglobin &gt;10 and &lt;12 g/dL) and/or thrombocytopenia (platelets &gt;100,000 and &lt;150,000/mm<sup>3</sup>)</p> <p><strong>or</strong></p> Lymphopenia (lymphocytes &gt;500 and &lt;1000/mm<sup>3</sup>) </td> </tr> <tr> <td>Moderate = 4</td> <td> <p>Cytopenia of autoimmune origin with neutropenia (ANC ≥500 and ≤1000/mm<sup>3</sup>) and/or anemia (hemoglobin ≥8 and ≤10 g/dL) and/or thrombocytopenia (platelets ≥50,000 and ≤100,000/mm<sup>3</sup>)</p> <p><strong>or</strong></p> Lymphopenia (lymphocytes ≤500/mm<sup>3</sup>) </td> </tr> <tr class="divider_bottom"> <td>High = 6</td> <td>Cytopenia of autoimmune origin with neutropenia (ANC &lt;500/mm<sup>3</sup>) and/or anemia (hemoglobin &lt;8 g/dL) and/or thrombocytopenia (platelets &lt;50,000/mm<sup>3</sup>)</td> </tr> <tr> <td rowspan="3">Biologic</td> <td rowspan="3"> </td> <td>No = 0</td> <td>Absence of any of the following biologic features</td> </tr> <tr> <td>Low = 1</td> <td>Clonal component and/or hypocomplementemia (low C4 or C3 or CH50) and/or hypergammaglobulinemia or high IgG level between 16 and 20 g/L</td> </tr> <tr> <td>Moderate = 2</td> <td>Presence of cryoglobulinemia and/or hypergammaglobulinemia or high IgG level &gt;20 g/L, and/or recent-onset hypogammaglobulinemia or recent decrease of IgG level (&lt;5 g/L)</td> </tr> </tbody></table></div><div class="graphic_footnotes">EULAR: European League Against Rheumatism; HRCT: high-resolution computed tomography; NYHA: New York Heart Association classification; DL<sub>CO</sub>: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; GFR: glomerular filtration rate; EMG: electromyogram; MRI: magnetic resonance imaging; CK: creatine kinase; ULN: upper limit of normal; PNS: peripheral nervous system; NCS: nerve conduction studies; CIDP: chronic inflammatory demyelinating polyneuropathy; CNS: central nervous system; ANC: absolute neutrophil count; C4: complement component 4; C3: complement component 3; CH50: hemolytic complement test; IgG: immunoglobulin G.</div><div class="graphic_reference">Adapted with permission from: Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjögren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69(6):1103-9. Copyright © 2010 BMJ Publishing Group Ltd.<br/>Updated with information from:

<ol>
<li>Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI): A user guide. RMD Open 2015; 1e000022.</li>
</ol></div><div id="graphicVersion">Graphic 117434 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
